{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:41:17Z","timestamp":1791222077637,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:00:00Z","timestamp":1489449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T00:00:00Z","timestamp":1489449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to investigate the treatment strategy, prognostic factors, and risk factors of early death in elderly patients (age\u2009\u2265\u200965 years) with diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Data from elderly patients diagnosed with DLBCL between 2008 and 2014 were collected for analysis. Patients who were younger and had a better performance status were more likely to receive intensive frontline treatment. The median progression-free survival (PFS) and overall survival were 15 and 21 months, respectively. Anthracycline-containing chemotherapy achieved a higher remission rate and showed a trend towards better overall survival but a higher risk of severe neutropenia. Multivariate analysis revealed that very old age (\u226581 years), a high-risk age-adjusted international prognostic index (aaIPI) score, and bone marrow involvement were associated with poorer PFS and overall survival. Progression of lymphoma was the major cause of death in the study population. In addition, approximately 25% of patients died within 120 days of being diagnosed. The risk factors for early mortality included very old age, a high-risk aaIPI score, and bone marrow involvement. The appearance of symptoms or signs of tumour lysis syndrome at diagnosis was associated with a trend towards early death.<\/jats:p>","DOI":"10.1038\/srep44282","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T11:24:13Z","timestamp":1489490653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Investigation on treatment strategy, prognostic factors, and risk factors for early death in elderly Taiwanese patients with diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"7","author":[{"given":"Shih-Feng","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Hua","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Tang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Fen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ching","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Fung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Chih","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,14]]},"reference":[{"key":"BFsrep44282_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","volume":"75","author":"J Campisi","year":"2013","unstructured":"Campisi, J. Aging, cellular senescence, and cancer. Annual review of physiology 75, 685\u2013705, doi: 10.1146\/annurev-physiol-030212-183653 (2013).","journal-title":"Annual review of physiology"},{"key":"BFsrep44282_CR2","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.2014.55.1432","volume":"32","author":"C Falandry","year":"2014","unstructured":"Falandry, C., Bonnefoy, M., Freyer, G. & Gilson, E. Biology of cancer and aging: a complex association with cellular senescence. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 32, 2604\u20132610, doi: 10.1200\/JCO.2014.55.1432 (2014).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep44282_CR3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMra0804615","volume":"361","author":"JH Hoeijmakers","year":"2009","unstructured":"Hoeijmakers, J. H. DNA damage, aging, and cancer. The New England journal of medicine 361, 1475\u20131485, doi: 10.1056\/NEJMra0804615 (2009).","journal-title":"The New England journal of medicine"},{"key":"BFsrep44282_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0889-8588(05)70274-4","volume":"14","author":"L Balducci","year":"2000","unstructured":"Balducci, L. & Extermann, M. Cancer and aging. An evolving panorama. Hematology\/oncology clinics of North America 14, 1\u201316 (2000).","journal-title":"Hematology\/oncology clinics of North America"},{"key":"BFsrep44282_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.1986.4.3.295","volume":"4","author":"DO Dixon","year":"1986","unstructured":"Dixon, D. O. et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 4, 295\u2013305 (1986).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep44282_CR6","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1200\/JCO.1988.6.12.1838","volume":"6","author":"JM Vose","year":"1988","unstructured":"Vose, J. M. et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin\u2019s lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 6, 1838\u20131844 (1988).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep44282_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England journal of medicine 346, 235\u2013242, doi: 10.1056\/NEJMoa011795 (2002).","journal-title":"The New England journal of medicine"},{"key":"BFsrep44282_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh, M. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The lancet oncology 7, 379\u2013391, doi: 10.1016\/S1470-2045(06)70664-7 (2006).","journal-title":"The lancet oncology"},{"key":"BFsrep44282_CR9","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/cncr.25582","volume":"117","author":"A Musolino","year":"2011","unstructured":"Musolino, A. et al. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Cancer 117, 964\u2013973, doi: 10.1002\/cncr.25582 (2011).","journal-title":"Cancer"},{"key":"BFsrep44282_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3109\/10428194.2011.600486","volume":"53","author":"A Meguro","year":"2012","unstructured":"Meguro, A. et al. Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leukemia & lymphoma 53, 43\u201349, doi: 10.3109\/10428194.2011.600486 (2012).","journal-title":"Leukemia & lymphoma"},{"key":"BFsrep44282_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3109\/10428194.2011.621565","volume":"53","author":"F Merli","year":"2012","unstructured":"Merli, F. et al. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly \u201cfit\u201d patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leukemia & lymphoma 53, 581\u2013588, doi: 10.3109\/10428194.2011.621565 (2012).","journal-title":"Leukemia & lymphoma"},{"key":"BFsrep44282_CR12","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1200\/JCO.2011.35.7442","volume":"30","author":"P Soubeyran","year":"2012","unstructured":"Soubeyran, P. et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 30, 1829\u20131834, doi: 10.1200\/JCO.2011.35.7442 (2012).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep44282_CR13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman, J. W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937\u2013951, doi: 10.1182\/blood-2009-03-209262 (2009).","journal-title":"Blood"},{"key":"BFsrep44282_CR14","doi-asserted-by":"crossref","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. The New England journal of medicine 329, 987\u2013994, doi: 10.1056\/NEJM199309303291402 (1993).","DOI":"10.1056\/NEJM199309303291402"},{"key":"BFsrep44282_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases 40, 373\u2013383 (1987).","journal-title":"Journal of chronic diseases"},{"key":"BFsrep44282_CR16","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00277-012-1463-9","volume":"91","author":"TL Lin","year":"2012","unstructured":"Lin, T. L. et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Annals of hematology 91, 1383\u20131391, doi: 10.1007\/s00277-012-1463-9 (2012).","journal-title":"Annals of hematology"},{"key":"BFsrep44282_CR17","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/annonc\/mdm563","volume":"19","author":"C Thieblemont","year":"2008","unstructured":"Thieblemont, C. et al. Non-Hodgkin\u2019s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Annals of oncology: official journal of the European Society for Medical Oncology\/ESMO 19, 774\u2013779, doi: 10.1093\/annonc\/mdm563 (2008).","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology\/ESMO"},{"key":"BFsrep44282_CR18","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson, B. D. et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 17, 1244 (1999).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep44282_CR19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00277-012-1623-y","volume":"92","author":"O Bairey","year":"2013","unstructured":"Bairey, O., Bar-Natan, M. & Shpilberg, O. Early death in patients diagnosed with non-Hodgkin\u2019s lymphoma. Annals of hematology 92, 345\u2013350, doi: 10.1007\/s00277-012-1623-y (2013).","journal-title":"Annals of hematology"},{"key":"BFsrep44282_CR20","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1023\/A:1008485722472","volume":"9","author":"E Maartense","year":"1998","unstructured":"Maartense, E. et al. Elderly patients with non-Hodgkin\u2019s lymphoma: population-based results in The Netherlands. Annals of oncology: official journal of the European Society for Medical Oncology\/ESMO 9, 1219\u20131227 (1998).","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology\/ESMO"},{"key":"BFsrep44282_CR21","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1002\/cncr.22188","volume":"107","author":"VR Grann","year":"2006","unstructured":"Grann, V. R. et al. Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma. Cancer 107, 1530\u20131541, doi: 10.1002\/cncr.22188 (2006).","journal-title":"Cancer"},{"key":"BFsrep44282_CR22","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain, S. M., Whaley, F. S. & Ewer, M. S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97, 2869\u20132879, doi: 10.1002\/cncr.11407 (2003).","journal-title":"Cancer"},{"key":"BFsrep44282_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1600-0609.2006.00644.x","volume":"76","author":"J Campbell","year":"2006","unstructured":"Campbell, J. et al. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. European journal of haematology 76, 473\u2013480, doi: 10.1111\/j.1600-0609.2006.00644.x (2006).","journal-title":"European journal of haematology"},{"key":"BFsrep44282_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1532-5415.1995.tb06377.x","volume":"43","author":"PA Parmelee","year":"1995","unstructured":"Parmelee, P. A., Thuras, P. D., Katz, I. R. & Lawton, M. P. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. Journal of the American Geriatrics Society 43, 130\u2013137 (1995).","journal-title":"Journal of the American Geriatrics Society"},{"key":"BFsrep44282_CR25","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1200\/JCO.2007.10.6559","volume":"25","author":"M Extermann","year":"2007","unstructured":"Extermann, M. & Hurria, A. Comprehensive geriatric assessment for older patients with cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 25, 1824\u20131831, doi: 10.1200\/JCO.2007.10.6559 (2007).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep44282_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jgo.2014.11.004","volume":"6","author":"VA Morrison","year":"2015","unstructured":"Morrison, V. A. et al. Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper. Journal of geriatric oncology 6, 141\u2013152, doi: 10.1016\/j.jgo.2014.11.004 (2015).","journal-title":"Journal of geriatric oncology"},{"key":"BFsrep44282_CR27","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1200\/JCO.1998.16.6.2065","volume":"16","author":"H Gomez","year":"1998","unstructured":"Gomez, H. et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin\u2019s lymphoma: results of a multivariate analysis. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 16, 2065\u20132069 (1998).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep44282_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1046\/j.1365-2141.2002.03565.x","volume":"118","author":"C Dumontet","year":"2002","unstructured":"Dumontet, C. et al. Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin\u2019s lymphoma: a GELA study. British journal of haematology 118, 210\u2013217 (2002).","journal-title":"British journal of haematology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep44282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep44282","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep44282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T23:59:17Z","timestamp":1671839957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep44282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,14]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,5,17]]}},"alternative-id":["BFsrep44282"],"URL":"https:\/\/doi.org\/10.1038\/srep44282","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,14]]},"assertion":[{"value":"13 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"44282"}}